Dendreon Corporation

The Board of Trustees of Leeland Stanford Jr. Univ.

Dendreon Pharmaceuticals LLC

Reiner Laus

Curtis L Ruegg

Thomas Graddis

Damir Vidovic

Hongyu Wu

Edgar George Engleman

Michael H Shapero

Ofir Moreno

David Duncan

Sateesh Kumar Natarajan

Itzhak Hakim

Damir Vidović

Feng Chen

Michael Diegel

Demao Yang

Lara Porter Stepan

Cathy McMahan

Larisa Tsavaler

Alberto Rivas

Stefanie Mandl

Thomas J Graddis

Alain Delcayre

Damis Vidovic

Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease.

Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.

Compositions and methods for the treatment of disease associated with TRP-P8 expression

Compositions and methods for the treatment of disease associated with Trp-p8 expression

HLA-DR-specific monoclonal antibodies are provided that are capable of inducing apoptosis in HLA-DR-expressing tumor cells. Certain exemplary HLA-DR-specific antibodies exhibit reduced levels of immunosuppressive activity. Antibodies of the present invention will find use in diagnostic methods as well as in compositions and methods for the treatment of cancers associated with HLA-DR expressing tumor cells.

HLA-DR specific antibodies, compositions and methods

Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.

Compositions and methods for dendritic cell-based immunotherapy

Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.

Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease

Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).

Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation

Disclosed are a novel prostatic acid phosphatase and corresponding coding region derived from mouse. Also disclosed is a method of producing an immune response against an autologous polypeptide tumor antigen by immunizing a subject with a xenogeneic polypeptide antigen, either alone, as part of a viral antigen construct, or as part of a pulsed dendritic cell preparation.

Composition and method for producing an immune response against tumor-related antigens

Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.

Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody

Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

Immunostimulatory composition

The present invention is directed to novel polynucleotides and the polypeptides encoded by them, each of which are specific to human prostate tumor cells. The present invention further provides chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides of the present invention. Also provided herein are methods for producing the polypeptides of the present invention, as are detection assays that detect the presence of tumor cells in tissue or bodily fluid samples and methods for identifying novel compositions which modulate the activity of prostate tumor antigens and the use of such compositions in diagnosis and treatment of disease.

Prostate tumor polynucleotide compositions and methods of detection thereof

Immunostimulatory method

Disclosed is a novel gene and growth arrest gene product encoded by the gene. Expression of the growth arrest gene B4B results in inhibition of cellular proliferation. The gene and gene product serve as markers of cancerous or pre-cancerous conditions, and as markers of immune states.

Growing community of inventors

Bellevue, WA, United States of America

Reiner Laus